EHA Library - The official digital education library of European Hematology Association (EHA)

UNUSUAL DISTRIBUTION OF INTERLEUKIN-10 C-592A GENE POLYMORPHISM IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA FROM NORTH-WESTERN RUSSIA
Author(s): ,
Sergey Kapustin
Affiliations:
Laboratory of Biochemistry,Russian Research Institute Of Haematology And Transfusiology,Saint-Petersburg,Russian Federation
,
Irina Zotova
Affiliations:
Russian Research Institute Of Haematology And Transfusiology,Saint-Petersburg,Russian Federation
,
Sergei Gritsaev
Affiliations:
Russian Research Institute Of Haematology And Transfusiology,Saint-Petersburg,Russian Federation
,
Jane Sidorova
Affiliations:
Laboratory of Biochemistry,Russian Research Institute Of Haematology And Transfusiology,Saint-Petersburg,Russian Federation
,
Irina Pavlova
Affiliations:
Laboratory of Immunohematology,Russian Research Institute Of Haematology And Transfusiology,Saint-Petersburg,Russian Federation
,
Anastasya Pavlova
Affiliations:
Laboratory of Immunohematology,Russian Research Institute Of Haematology And Transfusiology,Saint-Petersburg,Russian Federation
Stanislav Bessmeltsev
Affiliations:
Russian Research Institute Of Haematology And Transfusiology,Saint-Petersburg,Russian Federation
(Abstract release date: 05/18/17) EHA Library. Kapustin S. 05/18/17; 182808; PB2094
Dr. Sergey Kapustin
Dr. Sergey Kapustin
Contributions
Abstract

Abstract: PB2094

Type: Publication Only

Background
Primary immune thrombocytopenia (ITP) is a rare hematological disease with unknown etiology. It is characterized by heterogeneity of the laboratory parameters as well as the features of clinical manifestation. DNA polymorphism of several cytokine genes has been suggested to modulate the risk of ITP development or/and treatment response in distinct population groups. There is no data on the prevalence of cytokine gene polymorphisms in ITP patients from the North-Western region of Russia (NWR).

Aims
To establish the features of genotypes distribution for several cytokine promoter gene polymorphisms in ITP patients from NWR.

Methods
A total of 68 patients (59 women and 9 men) with chronic primary ITP were involved in the study. The median age of the group was 57 years (range: 24-77). The mean duration of ITP was 7 years (2-48). In 19 (32.2%) women, ITP was diagnosed before 30 years old; 26 (38.2%) patients (5 men and 21 women) were diagnosed at age 30-50 years; 23 (33.8%) patients (4 men and 19 women) developed ITP after 50 years old. The control group consisted of 240 healthy persons originated from NWR. Nucleotide variations in the genes coding for interleukin (IL)-1b (-31T/C), IL-6 (-174G/C), IL-10 (-592C/A) and tumor-necrosis factor alpha (TNFA -308 G/A) were discriminated by PCR and subsequent restriction analysis (PCR-RFLP). Intergroup differences in genotype frequencies were assessed by Fisher's exact method. Odds ratios (OR), their 95% confidence intervals (CI) and p-values were calculated by using the GraphPad Prism 5.0 software.

Results
The frequency of the IL-10 -592CC genotype was slightly increased in the ITP group when compared to controls (65.7% vs. 54.0% respectively; OR=1.6, 95% CI: 0.9-3.1, p=0.15). Interestingly, this variant of the IL-10 gene was more prevalent among women than men with ITP (71.2% vs. 25.0% respectively; OR=7.4, 95% CI: 1.4-40.5, p=0.016). When compared to controls, the IL-10 -592CC genotype was significantly overrepresented in the group of women with ITP (71.2% vs. 54.0%; OR=2.1, 95% CI: 1.1-4.2, p=0.044). On the contrary, in the group of affected men we observed the increase of persons who had IL-10 -592A allele (75.0% vs. 46.0% in control group; OR=3.5, 95% CI: 0.7-18.3, p=0.15). Genotype frequencies for other studied genes were similar between the patients and control group as well as between women and men with ITP. We have also found almost 2-fold increase of the IL-1b -31CC frequency in women diagnosed before 30 years old compared to other patients (15.8% vs. 8.2% respectively; OR=2.1, 95% CI: 0.4-10.5, p=0.39). The presence of the TNFA -308A allele was more often seen in patients diagnosed before 50 years old (26.7% vs. 8.7% in other ITP patients; OR=3.8, 95% CI: 0.8-18.8, p=0.12).

Conclusion
We suggest that the IL-10 -592CC genotype is associated with increased risk of ITP in women from NWR. On the other hand, the IL-10 -592A allele could be involved in pathogenesis of ITP in men. Further studies are needed to clarify the significance of TNFA and IL-1b gene polymorphism in ITP development.

Session topic: 31. Other Non-malignant hematopoietic disorders

Keyword(s): Immune thrombocytopenia (ITP), IL-10, Genetic, Gene polymorphism

Abstract: PB2094

Type: Publication Only

Background
Primary immune thrombocytopenia (ITP) is a rare hematological disease with unknown etiology. It is characterized by heterogeneity of the laboratory parameters as well as the features of clinical manifestation. DNA polymorphism of several cytokine genes has been suggested to modulate the risk of ITP development or/and treatment response in distinct population groups. There is no data on the prevalence of cytokine gene polymorphisms in ITP patients from the North-Western region of Russia (NWR).

Aims
To establish the features of genotypes distribution for several cytokine promoter gene polymorphisms in ITP patients from NWR.

Methods
A total of 68 patients (59 women and 9 men) with chronic primary ITP were involved in the study. The median age of the group was 57 years (range: 24-77). The mean duration of ITP was 7 years (2-48). In 19 (32.2%) women, ITP was diagnosed before 30 years old; 26 (38.2%) patients (5 men and 21 women) were diagnosed at age 30-50 years; 23 (33.8%) patients (4 men and 19 women) developed ITP after 50 years old. The control group consisted of 240 healthy persons originated from NWR. Nucleotide variations in the genes coding for interleukin (IL)-1b (-31T/C), IL-6 (-174G/C), IL-10 (-592C/A) and tumor-necrosis factor alpha (TNFA -308 G/A) were discriminated by PCR and subsequent restriction analysis (PCR-RFLP). Intergroup differences in genotype frequencies were assessed by Fisher's exact method. Odds ratios (OR), their 95% confidence intervals (CI) and p-values were calculated by using the GraphPad Prism 5.0 software.

Results
The frequency of the IL-10 -592CC genotype was slightly increased in the ITP group when compared to controls (65.7% vs. 54.0% respectively; OR=1.6, 95% CI: 0.9-3.1, p=0.15). Interestingly, this variant of the IL-10 gene was more prevalent among women than men with ITP (71.2% vs. 25.0% respectively; OR=7.4, 95% CI: 1.4-40.5, p=0.016). When compared to controls, the IL-10 -592CC genotype was significantly overrepresented in the group of women with ITP (71.2% vs. 54.0%; OR=2.1, 95% CI: 1.1-4.2, p=0.044). On the contrary, in the group of affected men we observed the increase of persons who had IL-10 -592A allele (75.0% vs. 46.0% in control group; OR=3.5, 95% CI: 0.7-18.3, p=0.15). Genotype frequencies for other studied genes were similar between the patients and control group as well as between women and men with ITP. We have also found almost 2-fold increase of the IL-1b -31CC frequency in women diagnosed before 30 years old compared to other patients (15.8% vs. 8.2% respectively; OR=2.1, 95% CI: 0.4-10.5, p=0.39). The presence of the TNFA -308A allele was more often seen in patients diagnosed before 50 years old (26.7% vs. 8.7% in other ITP patients; OR=3.8, 95% CI: 0.8-18.8, p=0.12).

Conclusion
We suggest that the IL-10 -592CC genotype is associated with increased risk of ITP in women from NWR. On the other hand, the IL-10 -592A allele could be involved in pathogenesis of ITP in men. Further studies are needed to clarify the significance of TNFA and IL-1b gene polymorphism in ITP development.

Session topic: 31. Other Non-malignant hematopoietic disorders

Keyword(s): Immune thrombocytopenia (ITP), IL-10, Genetic, Gene polymorphism

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies